Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06821497 |
| Synonyms | |
| Therapy Description |
PF-06821497 is an EZH2 inhibitor which may have anti-tumor activity (PMID: 29211475). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06821497 | PF06821497|PF 06821497 | EZH2 inhibitor 20 | PF-06821497 is an EZH2 inhibitor which may have anti-tumor activity (PMID: 29211475). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | POL | ESP | BGR | 4 |